Search results
Results from the WOW.Com Content Network
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
Researchers say a new study of kidney cancer offers hope for treating the disease using existing drugs. The study of the cancer at a single-cell level has discovered a potential drug target to ...
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
This is an accepted version of this page This is the latest accepted revision, reviewed on 18 January 2025. Medical condition Kidney cancer Other names Renal cancer Micrograph showing the most common type of kidney cancer (clear cell renal cell carcinoma). H&E stain. Specialty Oncology nephrology Urology Symptoms Blood in the urine, lump in the abdomen, back pain Usual onset After the age of ...
This is a table of drugs that are secreted in the kidney. Acid medication are, because of pH partition , secreted to a higher extent when urine is basic. In the same way, basic medications are secreted to a higher extent when urine is acidic.
Here's everything you need to know about the most common kidney cancer signs and who is most at risk for developing it. Skip to main content. 24/7 Help. For premium support please call: 800-290 ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [159] A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. [160]